Related Experiment Video
Updated: Jul 7, 2026

Zika Virus Infectious Cell Culture System and the In Vitro Prophylactic Effect of Interferons
Published on: August 23, 2016
Hepatitis C virus infection and interferon therapy in patients with Down syndrome
Yoko Miyoshi1, Hitoshi Tajiri, Mariko Okaniwa
1Department of Pediatrics, Osaka University Graduate School of Medicine, Osaka, Japan.
Insights
Interferon therapy for hepatitis C virus (HCV) infection shows unfavorable outcomes in children with Down syndrome (DS). These children did not clear HCV-RNA, unlike control groups, suggesting limited treatment efficacy.
Area of Science:
- Pediatric Hepatology
- Virology
- Genetics
Background:
- Hepatitis C virus (HCV) associated liver diseases present unique clinical features in children.
- The efficacy of interferon (IFN) therapy for HCV in pediatric Down syndrome (DS) patients requires further investigation.
Purpose of the Study:
- To survey the characteristics of liver diseases in children with Down syndrome.
- To evaluate the effectiveness of interferon treatment in pediatric patients with Down syndrome and HCV infection.
Main Methods:
- A questionnaire was distributed to pediatric hepatology specialists in Japan.
- Data were collected from 11 pediatric patients with Down syndrome and chronic HCV infection.
Main Results:
- None of the six Down syndrome patients treated with natural IFN-alpha for 24 weeks cleared HCV-RNA.
- In contrast, 50% of age- and sex-matched control children achieved sustained HCV-RNA clearance with the same IFN regimen.
- Baseline characteristics such as ALT levels, HCV genotype, and viral load were similar between Down syndrome patients and controls.
Conclusions:
- Interferon therapy for HCV infection appears less favorable in pediatric patients with Down syndrome compared to those without Down syndrome.
Background:
The clinical features of hepatitis C virus (HCV)-associated liver diseases, or the efficacy of interferon (IFN) therapy in children with Down syndrome (DS) remain to be elucidated. The purpose of the present paper was to survey the features of liver diseases in this subset of children and evaluate the efficacy of IFN treatment in those patients.
Methods:
A questionnaire was sent to 41 members of the Japan Society of Pediatric Hepatology. Ten of them reported on 11 patients with DS who had concomitant chronic HCV infection, providing information on liver disease and the response to IFN treatment.
Results:
Interferon therapy of 24 weeks duration using natural IFN-alpha was instituted in six of the 11 patients with DS, but none of the six patients cleared HCV-RNA from their serum. Among 12 age- and sex-matched control children who were treated with IFN using the same regimen against chronic HCV infection, half of them had a favorable response to IFN therapy with a sustained clearance of HCV-RNA from their serum. The major baseline features including alanine aminotransferase levels, HCV genotype and viral load were not apparently different between the six patients with DS and the 12 controls.
Conclusions:
IFN therapy for HCV infection in patients with DS may be unfavorable as compared with non-DS children.
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Hepatitis
Immunodeficiency Diseases
There are three main causes of immunodeficiency disorders...
Cytomegalovirus Disease
Viral Hepatitis I: Introduction
Retrovirus Life Cycles

